JACQUELINE CHANLATTE-GARCIA: Open Payments
NPI 1801819537 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$443 in 17 payments from 10 companies in 2025. Trend: 2023 $328 · 2024 $369 · 2025 $443
Food & beverage: $443
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 4 | $165 |
| Alexion Pharmaceuticals, Inc. | 3 | $73 |
| Lilly USA, LLC | 2 | $36 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Novo Nordisk Inc | 2 | $33 |
| ABBVIE INC. | 1 | $26 |
| HARMONY BIOSCIENCES LLC | 1 | $24 |
| ABIOMED | 1 | $22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: EVENITY, KOSELUGO, MOUNJARO, OPSUMIT, LINZESS, WAKIX, Ozempic, XIFAXAN.
Industry payments across NE — which companies pay providers there.
